Hexagon Bio Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
76
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$62M
- Investors
-
14
Hexagon Bio General Information
Description
Developer of antibody-drug conjugate payloads designed to support targeted cancer treatment. The company's research focuses on drug payloads with alternative mechanisms of action beyond topoisomerase and tubulin inhibition, enabling oncology drug developers to explore targeted therapies and address resistance associated with existing antibody-drug conjugate payloads.
Contact Information
Website
www.hexagonbio.comCorporate Office
- 1490 O'Brien Drive
- Suite E
- Menlo Park, CA 94025
- United States
Corporate Office
- 1490 O'Brien Drive
- Suite E
- Menlo Park, CA 94025
- United States
Hexagon Bio Timeline
Hexagon Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series C) | 23-Oct-2026 | $62M | Completed | Clinical Trials - Phase 1 | ||
| 4. Later Stage VC (Series B) | 13-Feb-2023 | Completed | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC (Series B) | 22-Sep-2021 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A) | 15-Sep-2020 | $47M | $55.3M | Completed | Startup | |
| 1. Seed Round | 18-Jul-2017 | $8.3M | $8.3M | Completed | Startup |
Hexagon Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C2 | ||||||||
| Series C1 | ||||||||
| Series C | ||||||||
| Series B | ||||||||
| Series A2 | ||||||||
| Series A1 | ||||||||
| Series A Prime | 15,421,955 | $0.000100 | 8% | $3.96 | $3.96 | 1x | $3.96 | 7.07% |
| Seed | 3,256,567 | $0.000100 | 8% | $2.58 | $2.58 | 1x | $2.58 | 1.49% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Hexagon Bio Comparisons
Industry
Financing
Details
Hexagon Bio Competitors (96)
One of Hexagon Bio’s 96 competitors is Exo Therapeutics, a Venture Capital-Backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Exo Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| etherna | Formerly VC-backed | Niel, Belgium | ||||
| Arvinas | Formerly VC-backed | New Haven, CT | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Agomab Therapeutics | Formerly VC-backed | Antwerp, Belgium |
Hexagon Bio Patents
Hexagon Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026227038-A2 | Eif4a modulators and uses thereof | Pending | 25-Apr-2025 | ||
| WO-2026227043-A1 | Substituted beta alanine conjugates and uses thereof | Pending | 25-Apr-2025 | ||
| WO-2025226868-A1 | Antibody drug conjugates and uses thereof | Pending | 23-Apr-2024 | ||
| EP-4805503-A1 | Methods for identification of compound interaction partners and compounds produced by gene clusters | Pending | 08-Nov-2023 | ||
| WO-2025101762-A1 | Methods for identification of compound interaction partners and compounds produced by gene clusters | Inactive | 08-Nov-2023 | C12N15/80 |
Hexagon Bio Signals
Hexagon Bio Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| bpd partners | Family Office | Minority | ||
| CPP Investments | Asset Manager | Minority | ||
| Casdin Capital | Venture Capital | Minority | ||
| Nextech Invest | Venture Capital | Minority | ||
| SoftBank Investment Advisers | Growth/Expansion | Minority |
Hexagon Bio Investments (1)
Hexagon Bio’s most recent deal was a Joint Venture with Developer of New Crop Protection Solutions (Corteva / Hexagon Bio). The deal was made on 22-Dec-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Developer of New Crop Protection Solutions (Corteva / Hexagon Bio) | 22-Dec-2025 | Joint Venture | Agricultural Chemicals |
Hexagon Bio FAQs
-
When was Hexagon Bio founded?
Hexagon Bio was founded in 2016.
-
Where is Hexagon Bio headquartered?
Hexagon Bio is headquartered in Menlo Park, CA.
-
What is the size of Hexagon Bio?
Hexagon Bio has 76 total employees.
-
What industry is Hexagon Bio in?
Hexagon Bio’s primary industry is Drug Discovery.
-
Is Hexagon Bio a private or public company?
Hexagon Bio is a Private company.
-
What is the current valuation of Hexagon Bio?
The current valuation of Hexagon Bio is .
-
What is Hexagon Bio’s current revenue?
The current revenue for Hexagon Bio is .
-
How much funding has Hexagon Bio raised over time?
Hexagon Bio has raised $256M.
-
Who are Hexagon Bio’s investors?
bpd partners, CPP Investments, Casdin Capital, Nextech Invest, and SoftBank Investment Advisers are 5 of 14 investors who have invested in Hexagon Bio.
-
Who are Hexagon Bio’s competitors?
Exo Therapeutics, etherna, Arvinas, CytomX Therapeutics, and Agomab Therapeutics are some of the 96 competitors of Hexagon Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process